Terns Pharmaceuticals, Inc. Change in payables and accrued liability

Change in payables and accrued liability of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in payables and accrued liability growth rates and interactive chart.


Highlights and Quick Summary

  • Change in payables and accrued liability for the quarter ending March 31, 2022 was $-731 Thousand (a -244.47% decrease compared to previous quarter)
  • Year-over-year quarterly Change in payables and accrued liability decreased by -17.03%
  • Annual Change in payables and accrued liability for 2021 was $1.73 Million (a -250.7% decrease from previous year)
  • Annual Change in payables and accrued liability for 2020 was $-1.15 Million (a -258.73% decrease from previous year)
  • Annual Change in payables and accrued liability for 2019 was $722 Thousand (a 47.95% increase from previous year)
  • Twelve month Change in payables and accrued liability ending March 31, 2022 was $-1.21 Million (a -170.18% decrease compared to previous quarter)
  • Twelve month trailing Change in payables and accrued liability decreased by -141.24% year-over-year
Trailing Change in payables and accrued liability for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-1.21 Million $1.73 Million $1.14 Million $2.94 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in payables and accrued liability of Terns Pharmaceuticals, Inc.

Most recent Change in payables and accrued liabilityof TERN including historical data for past 10 years.

Interactive Chart of Change in payables and accrued liability of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-0.73
2021 $0.51 $-0.11 $-0.88 $2.21 $1.73
2020 $-0.08 $1.69 $1.84 $1.33 $-1.15
2019 $1.64 $0.72
2018 $0.49

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.